ArticleFrontiers in nutrition2026
Diabetes-specific formula as meal replacement for individuals with type 2 diabetes mellitus and overweight or obesity: a Singapore expert consensus.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In Singapore, only one-quarter of patients with type 2 diabetes mellitus and overweight/obesity in the primary care setting are achieving clinical targets with a food-first approach to medical nutrition therapy. Diabetes-specific formula as meal replacement (DSF-MR) provides an evidence-based escalation of care but remains underutilised in practice. We developed expert consensus recommendations to support the use of DSF-MR in Singapore and across Asia. Methods: A multidisciplinary 11-member advisory board guided a multicomponent study that included an online healthcare professional survey, a narrative literature review, and structured consensus development. Survey insights shaped research questions and the narrative review, and collated findings were subsequently discussed at an advisory board meeting. Practical recommendations emerging from the meeting were finalised through two rounds of blinded online voting (>70% agreement) and then consolidated into a clinical algorithm for practice. Results: Eighteen practical, evidence-based recommendations achieved consensus. Collectively, they outline the clinical role of DSF-MR across three key applications: improving glycaemic control, supporting diabetes remission, and preserving muscle mass. Recommendations also address patient selection, integration within holistic care approaches, monitoring, and improving adherence, with the aim of optimising outcomes with DSF-MR. Conclusion: DSF-MR is supported by evidence as a versatile dietary intervention that can be integrated across the diabetes care continuum. These expert consensus recommendations address critical gaps in current practice and provide clear and actionable guidance for the use of DSF-MR in routine diabetes care across primary care and specialist settings in Singapore.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.